Revenio Group Corporation

Research Revenio Group Corporation (REG1V) on Bullrun: valuation model: 31.9% undervalued, market cap EUR 336.82M, P/E 21.5, dividend yield 3.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Revenio Group Corporation as 31.9% undervalued; latest market cap is EUR 336.82M; P/E is 21.5; dividend yield is 3.5%.

About Revenio Group Corporation

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings;

Frequently asked questions

Is Revenio Group Corporation overvalued or undervalued?

Bullrun's valuation model currently marks Revenio Group Corporation as 31.9% undervalued.

What is Revenio Group Corporation's market cap?

Revenio Group Corporation's market capitalization is EUR 336.82M.

What is Revenio Group Corporation's P/E ratio?

Revenio Group Corporation's price-to-earnings (P/E) ratio is 21.5.

Does Revenio Group Corporation pay a dividend?

Revenio Group Corporation has a dividend yield of 3.5%.

What does Revenio Group Corporation do?

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers;